Asia-Pacific Insulin Infusion Pumps Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Asia-Pacific Insulin Infusion Pumps Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

The Asia-Pacific Insulin Infusion Pump Market is expected to register a CAGR greater than 5% over the forecast period (2021 - 2027).

People with Covid-19 had a statistically greater incidence of type 2 diabetes and other kinds of diabetes in the Asia-Pacific region. Individuals with no history of diabetes who recovered from SARS-CoV-2 infections have been reported to develop insulin resistance and reduced insulin secretion. It has been proposed that integrated rather than disease-specific methods are needed for post-Covid syndrome diagnosis and therapy.

The conventional method of daily injections or an insulin pen can be replaced by an insulin infusion pump. Insulin infusion pumps alleviate discomfort, distribute insulin more precisely than injections, and prevent huge fluctuations in blood glucose levels. When utilizing pumps, mealtime planning is not necessary. Patients can use infusion pumps more easily as a result. Continuous subcutaneous insulin infusion is another name for insulin treatment (CSII). It is a reliable and adaptable way to administer insulin. The insulin pump has improved and is now more dependable than it ever was. Numerous technical developments have been made to CSII technology, including the incorporation of continuous glucose monitoring with the pump.

Therefore, owing to the aforementioned factors the studied market is anticipated to witness growth over the analysis period.

Key Market TrendsInsulin Infusion Pump Devices Dominating the Asia-Pacific Insulin Infusion Pump Market

An insulin pump is a device, which delivers insulin continuously or whenever required automatically. The pump mimics the human pancreas. The insulin infusion pump works as an alternative to the traditional system of daily injections or an insulin pen. Type 1 diabetes is caused by an autoimmune reaction in which the body's immune system attacks the insulin-producing beta cells of the pancreas. To maintain appropriate glucose levels, patients with Type 1 diabetes need daily insulin injections, usually up to 4 times a day. A chronically high level of glucose may lead to complications such as retinopathy and nephropathy.

Insulin pump therapy is a treatment in which insulin is continuously administered using a portable pump. The insulin is delivered into the patient's body through a subcutaneously inserted cannula. Because the insulin dosage can be adjusted accurately depending on day-to-day activities such as exercise and meal choice, it is expected to improve glucose management and helps prevent complications

An insulin pump has been demonstrated in studies to enhance diabetes management and reduce the risk of hypoglycemia. When using an insulin pump, many patients find that they have more freedom in the timing of their meals and activities. Sharing insulin pump data with the care team between office visits allows patients to get the most out of the time they spend with them during their sessions. Uploading pump data helps the care team to track patterns and, if necessary, make changes to your care plan. Insulin pumps use short-acting and rapid-acting insulin but are not long-acting since the pump is programmed to deliver a small amount continuously to keep your blood sugar levels even. Most insurance companies cover insulin pumps.

Australia and China are Expected to Dominate the Asia-Pacific Insulin Infusion Pump Market.

Among the Asia-Pacific countries, Australia and China dominate around 56% of the total Asia-Pacific Insulin Infusion Pump Market. This is mainly due to the high diabetes prevalence in these countries. China records the highest healthcare expenditure in the Asia-pacific region. According to the National Bureau of Statistics of China; MOH (China) in 2020 China’s expenditure on health is Yuan 7,217.5 billion. Expenditure includes government spending, collective spending, and private out-of-pocket spending on health care. In 2020, health expenditure in China equaled about 7.1 percent of the GDP, up from 6.67 percent in the previous year. Health insurance is voluntary in China, but the share of the population being covered by basic health insurance has grown quickly in the last ten years.

In 2021, according to Diabetes Australia, “The Australian health system spends USD 2.5 billion per annum directly on diabetes”. On top of this diabetes is a leading cause of heart disease, which costs the health system more than USD 2 billion per annum, chronic kidney disease which costs USD 1.7 billion, and stroke which costs USD 660 million. In Australia, neither Medicare nor the NDSS will pay the entire cost of an insulin pump. In the absence of private health insurance, insulin pumps can cost between USD 5000 to USD 10,000 or more. The price of an insulin pump is subsidized by several private health insurance providers. Insulin pump consumables such as pump sets and lines are an ongoing cost for the patient and are not usually covered by private health insurance, NDSS, or medicare. Although the pump and its supplies (tubing, insulin cartridges, and infusion sets) continue to be expensive, insurance coverage has improved considerably over the years.

Therefore, owing to the aforesaid factors the growth of the studied market is anticipated in the Asia-Pacific Region.

Competitive Landscape

The Asia-Pacific Insulin Infusion Pumps Market is consolidated by very few companies occupying the largest market share globally and especially in the Asia-Pacific region. Animas had to exit the insulin pump market, as the company has admitted that rising competition was the reason for them to leave the market.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

Please note: This publisher does offer titles that are created upon receipt of order. If you are purchasing a PDF Email Delivery option above, the report will take approximately 2 business days to prepare and deliver.